Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    STELARA Crohn's
Show Display Options
Rank Status Study
1 Recruiting A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Intervention: Drug: Ustekinumab
2 Not yet recruiting Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease
Condition: Crohn Disease
Intervention: Biological: Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra
3 Completed
Has Results
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: Ustekinumab 90 mg;   Drug: Ustekinumab 4.5 mg/kg;   Drug: Placebo SC;   Drug: Placebo IV
4 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Conditions: Crohn's Disease;   Inflammatory Bowel Disease;   IBD;   Colitis
Interventions: Drug: Group 1: Placebo;   Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg
5 Not yet recruiting Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Condition: Crohn Disease
Intervention: Drug: Ustekinumab
6 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Conditions: Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
7 Recruiting Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: JNJ-64304500;   Drug: Placebo;   Drug: Ustekinumab
8 Active, not recruiting
Has Results
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Conditions: Crohn's Disease;   Colitis;   IBD;   Inflammatory Bowel Disease
Interventions: Drug: Placebo SC;   Drug: Placebo IV;   Drug: Ustekinumab 90 mg SC q8w;   Drug: Ustekinumab 130 mg IV;   Drug: Ustekinumab 90 mg SC q12w
9 Completed
Has Results
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
Condition: Crohn's Disease
Interventions: Drug: Placebo (IP);   Drug: Ustekinumab 1mg/kg (IP);   Drug: Ustekinumab 3 mg/kg (IP);   Drug: Ustekinumab 6 mg/kg (IP);   Drug: Placebo IV - Responder - Placebo SC (MP);   Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP);   Drug: Ustekinumab IV - Responder - Placebo SC (MP);   Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP);   Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP);   Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
10 Recruiting Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
Conditions: Psoriasis;   Pregnancy;   Psoriatic Arthritis;   Crohn Disease
Intervention:
11 Recruiting Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Conditions: CVID;   Enteropathy;   Chronic Diarrhea;   Maldigestion;   Malabsorption
Intervention: Biological: Ustekinumab
12 Recruiting Tracking Biologics Along the Silk Road
Condition: Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative
Intervention:
13 Not yet recruiting Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells
Condition: Inflammatory Bowel Disease
Intervention: Biological: Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab
14 Not yet recruiting Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
Condition: Inflammatory Bowel Diseases
Interventions: Biological: Pneumococcal Pneumonia vaccine;   Biological: Influenza vaccine;   Biological: Hepatitis B vaccine

Study has passed its completion date and status has not been verified in more than two years.